Pharma

Your Article Summary

See Latest Articles

Court Grants Teva Summary Judgment Of Non-Infringement On Eloxatin
Teva Pharmaceutical Industries, 06/19/09

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Teva's favor on the issue of non-infringement with regard to Debiopharm's U.S. Patent No. 5,338,874. The patent is listed in the Orange Book for Sanofi-Aventis' chemotherapy medication Eloxatin, which had annual sales of approximately $1.3 billion in the United States for the twelve months that ended December 2008, based on IMS sales data.

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09

See All of Regulatory Issues